Autopsy report · NCT04828174
Anti-TRBC1 CAR-T Cell Therapy in Patients With TRBC1 Positive T Cell Malignancies
Cause of deathSlow enrollment
“The trial was suspended due to the inability to enroll qualified participants”
Life of this trial
- Suspended: paused, and may or may not restart.
- 9 participants planned (an estimate, not an actual count).
Vital statistics
- Status
- Suspended
- Phase
- Phase 1
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
- Sponsor type
- University, hospital or other
- Conditions
- Peripheral T Cell Lymphoma; Angioimmunoblastic T-cell Lymphoma; Anaplastic Lymphoma; Acute T Cell Leukemia; T-lymphoblastic Lymphoma
- Interventions
- anti-TRBC1 CAR-T cell therapy
- Participants
- 9 (planned, not actual)
- Sites
- 1
- Countries
- China
Trials that died the same way
- Department of Defense PTSD Adaptive Platform Trial - Intervention C - Daridorexant
“The trial has been temporarily suspended due to administrative issues” - Development of a Biomarker Directed Strategy to Ameliorate Common Toxicities From Conventional Chemotherapy
“Trial has been suspended due to lack of resource and staff” - A Trial in Painful Diabetic Peripheral Neuropathy With GRT3983Y
“Trial was stopped due to difficult enrolment” - The Dose Finding Study of DAOIB Added to tDCS for AD
“The trial was suspended due to the budget issue” - Autologous Stem Cells in Pediatric Patients With Dilated Cardiomyopathy
“Suspended because the lack of patients among the time this clinical trial was running.”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.